Capsaicin — Discount Pricing

Other medications in Pain & Inflammation

• Carisoprodol
• Chlorzoxazone
• Codeine
• Dantrolene
• Diclofenac Gel
• Diclofenac Patch
• Diflunisal
• Dihydroergotamine

About Capsaicin

Capsaicin, the active component found in chili peppers, offers a surprising pathway to pain relief. This topical medication is widely used to soothe various types of chronic pain, from nerve discomfort to arthritis. At TheDrugClub, we understand that managing chronic conditions can be costly, and we're dedicated to helping our members save on essential medications like capsaicin.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Capsaicin is approved for (FDA label)

QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. QUTENZA is a TRPV1 channel agonist indicated for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 7, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Capsaicin (FDA label)

QUTENZA topical system contains 8% capsaicin (640 mcg per cm 2 ). Each topical system contains a total of 179 mg of capsaicin. Each topical system is 14 cm x 20 cm (280 cm 2 ) and consists of an adhesive side containing the active substance and an outer surface backing layer. The adhesive side is covered with a removable, clear, unprinted, diagonally cut, release liner. The outer surface of the backing layer is imprinted with “capsaicin 8%”. QUTENZA contains 8% capsaicin (640 mcg per cm 2 ). Each topical systems contains a total of 179 mg of capsaicin. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3ffbbcb0-ad93-4f15-bb38-5da76a71c735. SPL document ID: fca75aa2-8651-42c5-9a72-74054a10452b. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Capsaicin (FDA label)

The following serious adverse reactions are discussed elsewhere in the labeling: Severe Irritation Due to Accidental Exposure of Eyes, Skin, Respiratory Tract, and Mucous Membranes [see Warning and Precautions ( 5.1 )] Application-Associated Pain [see Warnings and Precautions ( 5.2 )] Increase in Blood Pressure [see Warnings and Precautions ( 5.3 )] Sensory Function Reduction [see Warning and Precautions ( 5.4 )] Severe Application Site Burns ​[see Warning and Precautions ( 5.5 )] The most common adverse reactions (≥5% and greater than control) in all controlled clinical trials are application site erythema, application site pain, and application site pruritus. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Averitas Pharma at 1-877-900-6479 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 3ffbbcb0-ad93-4f15-bb38-5da76a71c735. SPL document ID: fca75aa2-8651-42c5-9a72-74054a10452b. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Capsaicin (FDA label)

Severe Irritation with Unintended Capsaicin Exposure: Capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others. (See Full Prescribing Information for detailed instructions on how to manage this risk. ( 2.1 , 5.1 ) Application-Associated Pain: Patients may experience substantial procedural pain and burning upon application of QUTENZA and following removal of QUTENZA. Prepare to treat acute pain during and following the application procedure with local cooling and/or appropriate analgesic medication. ( 5.2 ) Increase in Blood Pressure: Transient increases in blood pressure may occur with QUTENZA treatment.

Source: FDA prescribing information (DailyMed). Set ID: 3ffbbcb0-ad93-4f15-bb38-5da76a71c735. SPL document ID: fca75aa2-8651-42c5-9a72-74054a10452b. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Capsaicin (FDA label)

No clinical drug interaction studies have been performed. Data from in vitro cytochrome P450 inhibition and induction studies show that capsaicin does not inhibit or induce liver cytochrome P450 enzymes at concentrations which far exceed those measured in blood samples. Therefore, interactions with systemic medicinal products are unlikely.

Source: FDA prescribing information (DailyMed). Set ID: 3ffbbcb0-ad93-4f15-bb38-5da76a71c735. SPL document ID: fca75aa2-8651-42c5-9a72-74054a10452b. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.